<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00787644</url>
  </required_header>
  <id_info>
    <org_study_id>GLITZ Asthma</org_study_id>
    <nct_id>NCT00787644</nct_id>
  </id_info>
  <brief_title>Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)</brief_title>
  <acronym>GLITZ</acronym>
  <official_title>A Randomized, Placebo-Controlled Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics. (The GLITZ Asthma Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vermont</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Lung Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Asthmatics who are significantly overweight tend to have more severe symptoms, more flare
      ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.

      Researchers believe this occurs because excess adipose tissue (fat) in the bosy can cause
      higher-than-normal levels of leptin and lower levels of adiponectin in the blood.

      The researchers of this study are testing a medication called pioglitazone in overweight
      asthmatics because they believe it can help regulate leptin and adiponectin and that this may
      improve symptoms of asthma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in this study will be randomly assigned (like the flip of a coin) to
      pioglitazone or placebo (an inactive pill). They will be given study medication to take every
      day for 12 weeks (3 months).

      Participants will complete a number of asthma-related questionnaires and a variety of
      pulmonary function tests. Participants will undergo physical exams, an electrocardiogram, and
      blood sampling to measure leptin, adiponectin, markers of inflammation, blood cell counts,
      glucose levels, BNP hormone levels, and liver function.

      To monitor participants throughout the study, follow-up visits will be done at 2, 6, and 12
      weeks after starting study drug. At these visits many of the pulmonary function tests and
      questionnaires will be repeated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    new safety concerns which emerged about pioglitazone during the trial
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PC20</measure>
    <time_frame>12 weeks</time_frame>
    <description>Airway reactivity will be measured with methacholine challenge testing following ATS guidelines.
This is the concentration of methacholine that produces a 20% decrease in lung function (measured by forced expiratory volume in 1 second)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Asthma</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (inert tablet)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Asthma diagnosed by a physician at least 1 year prior to study enrollment

          -  Poorly-controlled asthma at study enrollment

          -  Non smokers (stopped smoking at least 1 year ago) and limited lifetime history of
             smoking

          -  Body mass index 30-60

          -  Responds to methacholine challenge test with PC20 of &lt;16 mg/ml

          -  On a stable dose of inhaled corticosteroid for at least 4 weeks prior to study entry

          -  FEV1 &gt; 60% predicted

          -  Able to obtain weekly weights at home

        Exclusion Criteria:

          -  Systemic steroids within the past 4 weeks

          -  Lung pathology other than asthma

          -  Other significant non-pulmonary co-morbidities such as: coronary artery disease,
             peripheral vascular disease, cerebrovascular disease, congestive heart failure with an
             ejection fraction &lt;50%, liver disease or elevated liver enzymes at baseline,
             malignancy (excluding non-melanoma skin cancers), AIDS, renal failure with serum
             creatinine &gt;3.0, or disorders requiring steroid treatment such as vasculitis, lupus,
             rheumatoid arthritis

          -  B-type natriuretic peptide (BNP) &gt;400pg/ml

          -  Pregnant or lactating

          -  Currently taking a beta blocker, a CYP2C8 inhibitor or inducer such as gemfibrozil or
             rifampin, a TZD (thiazolidinedione), or allergic to TZD

          -  Taking antioxidants (if taking a multivitamin must be on a stable regimen prior to
             enrollment)

          -  Illicit drug use within the past year

          -  Current/active upper respiratory infection (if active URI, wait until asymptomatic for
             1 week to enroll)

          -  Asthma exacerbation within the past 4 weeks (includes ER, urgent care, or hospital
             visits due to asthma resulting in an increase in asthma-related medications)

          -  Undergoing evaluation for sleep apnea, or plans to institute treatment for sleep apnea
             (patients on a stable treatment regimen for sleep apnea for the last 3 months will be
             allowed to participate)

          -  Clinically significant abnormalities present on screening 12-lead electrocardiogram

          -  Women of childbearing potential using oral contraceptives who are not willing to use a
             second method of contraception during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne E Dixon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Vermont Lung Center at the University of Vermont</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Vermont Lung Center at the University of Vermont</name>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <zip>05446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nhlbi.nih.gov/health/dci/Diseases/Asthma/Asthma_WhatIs.html</url>
    <description>Asthma informational website</description>
  </link>
  <link>
    <url>http://www.ginasthma.com/</url>
    <description>Asthma informational website</description>
  </link>
  <reference>
    <citation>Hashimoto Y, Nakahara K. Improvement of asthma after administration of pioglitazone. Diabetes Care. 2002 Feb;25(2):401.</citation>
    <PMID>11815521</PMID>
  </reference>
  <reference>
    <citation>Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, Lee MK, Kim UH, Lee YC. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol. 2006 Jul;118(1):120-7. Epub 2006 May 19.</citation>
    <PMID>16815147</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2008</study_first_submitted>
  <study_first_submitted_qc>November 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2008</study_first_posted>
  <results_first_submitted>January 8, 2015</results_first_submitted>
  <results_first_submitted_qc>February 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 26, 2015</results_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Anne Dixon</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Adipose Tissue</keyword>
  <keyword>Asthmatics</keyword>
  <keyword>Pioglitazone</keyword>
  <keyword>Actos</keyword>
  <keyword>Obesity</keyword>
  <keyword>Exacerbation</keyword>
  <keyword>Fat</keyword>
  <keyword>Overweight</keyword>
  <keyword>Leptin</keyword>
  <keyword>Adiponectin</keyword>
  <keyword>Wheezing</keyword>
  <keyword>Vermont</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>5 participants did not qualify for randomization as they had a negative methacholine.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1. Pioglitazone</title>
          <description>Pioglitazone: Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)</description>
        </group>
        <group group_id="P2">
          <title>2. Placebo</title>
          <description>Placebo: Matching placebo (inert tablet)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1. Pioglitazone</title>
          <description>Pioglitazone: Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)</description>
        </group>
        <group group_id="B2">
          <title>2. Placebo</title>
          <description>Placebo: Matching placebo (inert tablet)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PC20</title>
          <units>mg/ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.60" spread="5.91"/>
                    <measurement group_id="B2" value="1.99" spread="3.08"/>
                    <measurement group_id="B3" value="1.90" spread="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PC20</title>
        <description>Airway reactivity will be measured with methacholine challenge testing following ATS guidelines.
This is the concentration of methacholine that produces a 20% decrease in lung function (measured by forced expiratory volume in 1 second)</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1. Pioglitazone</title>
            <description>Pioglitazone: Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)</description>
          </group>
          <group group_id="O2">
            <title>2. Placebo</title>
            <description>Placebo: Matching placebo (inert tablet)</description>
          </group>
        </group_list>
        <measure>
          <title>PC20</title>
          <description>Airway reactivity will be measured with methacholine challenge testing following ATS guidelines.
This is the concentration of methacholine that produces a 20% decrease in lung function (measured by forced expiratory volume in 1 second)</description>
          <units>mg/ml</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.08" spread="7.42"/>
                    <measurement group_id="O2" value="2.37" spread="15.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1. Pioglitazone</title>
          <description>Pioglitazone: Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)</description>
        </group>
        <group group_id="E2">
          <title>2. Placebo</title>
          <description>Placebo: Matching placebo (inert tablet)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Anne Dixon</name_or_title>
      <organization>University of Vermont</organization>
      <phone>802 656 3525</phone>
      <email>anne.dixon@uvm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

